Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Sep;20(9):1970-8.
doi: 10.1158/1055-9965.EPI-11-0139. Epub 2011 Aug 16.

Autoantibodies to mesothelin in infertility

Judith L Luborsky  1 , Yi Yu, Seby L Edassery, Jade Jaffar, Yuan Yee Yip, Pu Liu, Karl Eric Hellstrom, Ingegerd Hellstrom
Affiliations

Autoantibodies to mesothelin in infertility

Judith L Luborsky et al. Cancer Epidemiol Biomarkers Prev. 2011 Sep.

Abstract

Background: According to extensive epidemiologic data, infertility is associated with increased ovarian cancer risk. Previous studies showed that both women with infertility and those with ovarian cancer have autoantibodies to ovarian antigens. The objective was to determine if women with infertility have antibodies to mesothelin, a well-characterized ovarian cancer antigen.

Methods: Sera were obtained from women with infertility (n = 109), ovarian cancer (n = 28), benign ovarian tumors or cysts (n = 24), and from healthy women (n = 152). Infertility included those with a risk for ovarian cancer; endometriosis (n = 23), ovulatory dysfunction (n = 17), premature ovarian failure (POF; n = 25) and unexplained infertility (n = 44). Sera were assayed for mesothelin antibodies and for circulating mesothelin antigen by immunoassay and compared with assay control sera (n = 16) to determine a positive result.

Results: Mesothelin antibodies were significantly more frequent in women with prematurely reduced ovarian function including ovulatory dysfunction (59%), ovarian failure (44%) and unexplained infertility (25%) compared with controls. In contrast, women with endometriosis, who also have a high risk for ovarian cancer, did not have mesothelin antibodies. Serum levels of mesothelin were rarely elevated in women with infertility but were high in most patients with ovarian cancer.

Conclusions and impact: We show for the first time that antibodies to mesothelin, a well-characterized ovarian cancer antigen, occur in some women with epidemiologic risk for ovarian cancer. The results suggest it may be possible to identify which women with infertility have ovarian cancer risk.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Box plots of mesothelin antibody shown as optical density (OD) values by study group. Sera were tested at 1:20 (upper graph) and 1:100 (lower graph). Each box plot shows the median (50th percentile; dark bar), values to the 1.5 interquartile range (whiskers), 25th–75th percentile range (box) and outliers (○, ★). The horizontal dotted line shows the cutoff value (mean serum control OD + 2SD) used to determine antibody positive results as summarized in Table 2.
Figure 2
Figure 2
Box plot of circulating mesothelin antigen levels (ng/mL) by study group. The box plot is described in Figure 1. The horizontal dotted line shows the mean normal value + 2SD for reference. Mean values for each group are summarized in Table 2.
Figure 3
Figure 3
Comparison of mesothelin antibody and circulating antigen in ovarian cancer (●) and benign tumor (△) groups. Mesothelin and anti-mesothelin were correlated in ovarian cancer (correlation coefficient corrected for age = 0.49, p=0.02). However, not all individuals with elevated mesothelin had anti-mesothelin antibodies.
See this image and copyright information in PMC

References

    1. Tortolero-Luna G, Mitchell MF. The epidemiology of ovarian cancer. J Cell Biochem Suppl. 1995;23:200–7. - PubMed
    1. Venn A, Healy D, McLachlan R. Cancer risks associated with the diagnosis of infertility. Best Pract Res Clin Obstet Gynaecol. 2003;17:343–67. - PubMed
    1. Runnebaum IB, Stickeler E. Epidemiological and molecular aspects of ovarian cancer risk. J Cancer Res Clin Oncol. 2001;127:73–9. - PubMed
    1. Ness RB, Cramer DW, Goodman MT, Kjaer SK, Mallin K, Mosgaard BJ, et al. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol. 2002;155:217–24. - PubMed
    1. Rossing MA, Tang MT, Flagg EW, Weiss LK, Wicklund KG. A case-control study of ovarian cancer in relation to infertility and the use of ovulation-inducing drugs. Am J Epidemiol. 2004;160:1070–8. - PubMed

Publication types